MotzerRJHutsonTETomczakPMichaelsonMDBukowskiRMOudardSOverall survival and updated results for Sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol2009; 27 (August(1): 3584–90.
2.
CuneoKCGengLFuAOrtonDHallahanDEChakravarthyAB. SU11248 (Sunitinib) sensitizes pancreatic cancer to the cytotoxic effects of ionizing radiation. Int J Radiat Oncol Biol Phys2008; 71: 873–9.
3.
KasibhatlaMSteinbergPMeyerJErnstoffMSGeorgeDJ. Radiation therapy and sorafenib: clinical data and rationale for the combination in metastatic renal cell carcinoma. Clin Genitourin Cancer2007; 5 (March(4)): 291–4.
4.
TausskyDSoulièresD. Hypofractionated radiotherapy with concomitant Sunitinib—is there a radiosensitizing effect?Can J Urol2009; 16 (April(2)): 4599–600.
5.
EscudierBPluzanskaAKoralewskiPRavaudABracardaSSzczylikC, AVOREN Trial Investigators. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet2007; 370 (December(9605)): 2103–11.
6.
PetersNARichelDJVerhoeffJJStalpersJJ. Bowel perforation after radiotherapy in a patient receiving sorafenib. J Clin Oncol2008; 26 (May(14)): 2405–6.
7.
SenanSSmitEF. Design of clinical trials of radiation combined with antiangiogenic therapy. Oncologist2007; 12 (April(4)): 465–77.
8.
KozinSVBoucherYHicklinDJBohlenPJainRKSuitHD. Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res2001; 61: 39–44.
